Review Outlines Vascular Smooth Muscle Cell Senescence as Therapeutic Target for Cardiovascular Diseases

A peer-reviewed scientific review evaluates how targeting vascular smooth muscle cell senescence with senolytics or molecular reprogramming could provide a therapeutic avenue to address age-related vascular dysfunction.

A scientific review published in the Journal of Cardiovascular Pharmacology detailed how chronic cardiometabolic stress and telomere attrition drive vascular smooth muscle cells (VSMCs) into senescence.

The authors described the molecular pathways involved in this transition, including p53/p21, p16/Rb, and persistent DNA-damage signaling.

The publication highlighted that the senescence-associated secretory phenotype (SASP) of VSMCs leads to calcification, extracellular matrix remodeling, and chronic inflammation, contributing to atherosclerosis and hypertension.

The review assessed therapeutic interventions targeting these pathways, specifically categorizing them into senolytics, senomorphics, metabolic modulators, and molecular reprogramming.

Cardiovascular diseases remain a leading cause of mortality in older populations, and therapies targeting the underlying cellular aging process, rather than symptoms, represent a shift in the field.

Establishing a theoretical link between VSMC senescence and major vascular disorders helps define clear biological targets for preclinical development.

Translational application is still restricted by the challenge of delivery and systemic toxicity, making targeted therapeutic approaches highly desirable.

The review validates the therapeutic hypotheses of companies in the cellular senescence space by outlining the vast clinical potential in cardiovascular health.

While many senolytic and reprogramming developers have historically prioritized localized delivery (such as ocular or musculoskeletal indications) to avoid systemic toxicity, this analysis highlights the massive, untapped market of systemic vascular rejuvenation.

Preclinical studies validating whether systemically or selectively delivered senolytic and reprogramming compounds can safely reverse vascular calcification in animal models.